Search company, investor...
Cardionomic company logo


Founded Year



Debt | Alive

Total Raised


Last Raised

$5M | 1 yr ago

About Cardionomic

Cardionomic addresses Acute Decompensated Heart Failure's root cause of reduced contractility. The therapy uses neuromodulation to benignly increase contractility, thus improving cardiac output therefore increasing renal flow and end organ perfusion. Benignly increasing contractility decreases negative hormonal signaling, and improves in-hospital morbidity/mortality.

Headquarters Location

601 Campus Drive Suite 12

New Brighton, Minnesota, 55112,

United States


Missing: Cardionomic's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Cardionomic's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Cardionomic

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Cardionomic is included in 2 Expert Collections, including Medical Devices.


Medical Devices

9,215 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Health IT

7,901 items

Cardionomic Patents

Cardionomic has filed 1 patent.

The 3 most popular patent topics include:

  • Cardiac arrhythmia
  • Cardiovascular physiology
  • Neurophysiology
patents chart

Application Date

Grant Date


Related Topics




Cardiac arrhythmia, Cardiovascular physiology, Cardiology, Beta blockers, Cardiac anatomy


Application Date


Grant Date



Related Topics

Cardiac arrhythmia, Cardiovascular physiology, Cardiology, Beta blockers, Cardiac anatomy



Latest Cardionomic News

11:00 EDT Pulse Technologies' Electrode Surface Treatment Chosen for Cardiac Device

May 16, 2022

News provided by Share this article Share this article Pulse Technologies' HSR™ electrode surface treatment is now part of Cardionomic's Cardiac Pulmonary Nerve Stimulation (CPNS) System for treating heart failure. QUAKERTOWN, Pa., May 16, 2022 /PRNewswire/ -- Pulse Technologies Inc. has announced that its proprietary Hierarchical Surface Restructuring (HSR™) technology is being utilized as part of Cardionomic's Cardiac Pulmonary Nerve Stimulation (CPNS) System for treating patients suffering from Acute Decompensated Heart Failure (ADHF). Said Steve Goedeke, CEO of Cardionomic, "Hierarchical Surface Restructuring is an enabling technology for Cardionomic as we develop our novel therapy intended to treat Acute Decompensated Heart Failure." The groundbreaking HSR™ patented technology modifies the surface of implantable electrodes and microelectrode arrays. The process allows an engineered surface that not only meets clients' precise performance requirements, but can enhance charge storage capacity, increase capacitance, and decrease impedance. HSR™ technology eliminates the risk of delamination, cracking and flaking associated with surface coatings, resulting in unparalleled durability. These improvements can enable smaller devices that have lower material costs and offer patient benefits. Images of hierarchically restructured electrodes for various neural applications: a) cylindrical electrode, b) helix electrode for cardiac rhythm management, c) rivet-style electrode for an electrophysiology mapping catheter and d) a cylindrical electrode for percutaneous spinal cord stimulation. SEM micrographs of the hierarchical surface structure on the surface of a paddle-lead for spinal cord stimulation; hierarchically structured electrodes consist of topographic features spanning a variety of length scales. The groundbreaking HSR™ patented technology modifies the surface of implantable electrodes and microelectrode arrays. "Our engineered surfaces deliver highly customizable and tunable surface characteristics, as well as durable electrochemical performance for a wide range of neural and cardiac interfacing applications ranging from neuromodulation to cardiac rhythm and cardiac mapping catheters," said Joe Rosato, CEO of Pulse Technologies, Inc. "We are excited to pair our HSR™ technology with Cardionomic's innovative Cardiac Pulmonary Nerve Stimulation System and play a role in treating heart failure." About Pulse Technologies Pulse Technologies, Inc. is an advanced technology, engineering and contract manufacturing company focused on active implantable medical device components and assemblies. Since its founding in 1993, Pulse has made significant investment in next-generation capabilities, including specialized surfaces and coatings. For more information on the company and its technologies, please visit . About Cardionomic Cardionomic, Inc. is a privately held U.S. company that designs and produces devices to address heart failure. For more information on the company and its products, please visit . The CPNS System is an investigational device and is limited by Federal (or United States) Law to investigational use.

Cardionomic Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Cardionomic Rank

Cardionomic Frequently Asked Questions (FAQ)

  • When was Cardionomic founded?

    Cardionomic was founded in 2015.

  • Where is Cardionomic's headquarters?

    Cardionomic's headquarters is located at 601 Campus Drive, New Brighton.

  • What is Cardionomic's latest funding round?

    Cardionomic's latest funding round is Debt.

  • How much did Cardionomic raise?

    Cardionomic raised a total of $50M.

  • Who are the investors of Cardionomic?

    Investors of Cardionomic include New Enterprise Associates, Ascension Ventures, Ascension, Cleveland Clinic Ventures and Integer.

  • Who are Cardionomic's competitors?

    Competitors of Cardionomic include NeuroPace, Verily Life Sciences, Theranica, Orchestra BioMed, Stimdia Medical, Cala Health, Lungpacer Medical, Saluda Medical, Rune Labs, BrainQ and 33 more.

Compare Cardionomic to Competitors

Cala Health

Cala Health develops wearable neuromodulation therapies to deliver individualized peripheral nerve stimulation. It was founded in 2014 and is based in San Mateo, California.


BrainsGate develops a technology for modulation of cerebro-vascular properties through neuro-stimulation of the spheno-palatine ganglion. Affected properties are central to many CNS disorders - blood vessel permeability and blood flow. Currently targeted applications include treatment of ischemic stroke and drug delivery to the CNS through modifying the permeability of the blood brain barrier. The Company has initiated clinical trials, delivering a chemotherapeutic agent to primary brain tumor patients.)


ShiraTronics develops an approach to treat migraine headaches. The company is focused on developing and clinically testing its neuromodulation technology

SetPoint Medical Logo
SetPoint Medical

SetPoint Medical is developing a bioelectronic medicine platform using a small implanted device that activates the body's natural Inflammatory Reflex and produces a systemic anti-inflammatory effect.

Neuros Medical Logo
Neuros Medical

Neuros Medical focuses on the development of proprietary therapies for unmet needs to patients worldwide. The company’s patented platform technology, Electrical Nerve Block, focuses on the treatment of chronic pain in a variety of applications including post-amputation pain, chronic post surgical pain, and chronic migraine.


Nēsos aims to transform disease treatment by developing brain interfaces that help the brain regain control of immune function.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.